Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments and capital allocation.
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
Greg Rodetis; Senior Vice President, Treasurer and Head of Investor Relations; Becton Dickinson and Co Thomas Polen; Chairman of the Board, President, Chief Executive Officer; Becton Dickinson and Co ...
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.
BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after ...
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback